Close menu




July 2nd, 2021 | 13:35 CEST

Netflix, wallstreet:online, Commerzbank: Where shareholders get their money's worth

  • Investments
Photo credits: pixabay.com

'Something to do with media' - years ago, this was the career goal of many graduates. But the reality in the media industry at the time was anything but dreamlike: The Neuer Markt went belly-up, and the media industry also had to cut back. Added to this was digitization, which turned many traditional business models upside down. In the meantime, however, the industry has consolidated - and is setting out for new shores.

time to read: 3 minutes | Author: Nico Popp
ISIN: NETFLIX INC. DL-_001 | US64110L1061 , WALLSTREET:ONLINE INH ON | DE000A2GS609 , COMMERZBANK AG | DE000CBK1001

Table of contents:


    Netflix: This calculation worked out

    Netflix is a prime example of how good money can be made with media. It is hard to imagine German living rooms without this streaming service. Netflix is also popular in most other countries around the world. Many young consumers watch series and movies in English anyway and get their money's worth with Netflix. The streaming provider relied on costly in-house productions early on; the concept has paid off. The lavish productions attracted subscribers. When a series is the topic of conversation in the schoolyard, campus or office kitchen, that is the best advertising.

    In 2020, Netflix increased its revenue by 24% to USD 25 billion. Profits were USD 2.8 billion, a whopping 47.9% higher than the previous year. Meanwhile, Netflix has more than 200 million paying subscribers. With that kind of support, it is easy to invest in the future. While years ago, traditional TV was predominant, and people rushed to sit in front of the TV at 8:15 p.m., services like Netflix have changed our viewing habits. Even classic TV viewers are now using media libraries more often and watching TV when it suits them. Netflix is a success story. However, the stock has been stuck in a sideways movement for about a year. The potential is accordingly limited.

    wallstreet:online: How the Berliners turn EUR 1 into EUR 16

    wallstreet:online's potential is anything but limited. Two weeks ago, the analysts at Warburg Research announced a price target of EUR 34. wallstreet:online is an operator of financial forums and news sites around the stock market. For the past 18 months, wallstreet:online has also been active in the brokerage business with its Smartbroker. Customers took up the offer in large numbers and ensured that the share quadrupled since the beginning of 2020. Since Smartbroker has been on the market, wallstreet:online's market capitalization has increased by a whopping EUR 280 million. The figure becomes more impressive the more one puts the value growth in context with the initial investments. As can be seen from the annual reports, wallstreet:online invested only around EUR 7.3 million in Smartbroker in 2019 and 2020. In addition, there was marketing for about EUR 10 million. The EUR 17.3 million invested at that time has thus increased more than sixteenfold in terms of market capitalization - a good indication that the Berliners understand their business and can turn even small investments into big successes.

    After Smartbroker already had 70,000 customers at the end of 2020, wallstreet:online called out the target of 200,000 customers by the end of 2021. Since 55,000 customers were added in the first quarter of 2021 alone, the Warburg analysts expect wallstreet:online to reach its targets. To create even more synergies between media portals and brokers, the Company recently raised EUR 5 million. The goal: to invest in IT and growth. Given the already intact growth story, it is to be expected that the latest investments will also be reflected positively in the share price. The Media and Brokerage divisions complement each other perfectly. The share has consolidated in recent weeks and is correspondingly attractive with a long-term perspective.

    Is Commerzbank saving itself to death?

    To invest in the Commerzbank share, the perspective should also be long - even better, very long. The bank is in the middle of a restructuring phase. If you take a closer look at Frankfurt's financial center, you might get the impression that one restructuring follows the next in the banking towers. Commerzbank's measures, eliminating 10,000 jobs and around 340 branches, will also initially cost money. It is also not clear whether the measures are the right ones in the long term - after all, proximity to the customer is crucial for successful banking. Although investment banking has been the primary source of income recently, the prospect of at least moderately rising interest rates could nourish hopes of a comeback for the bread-and-butter lending business. However, the extent to which this can be revived with just a few employees remains an open question. The Commerzbank share is languishing, and that will not change anytime soon.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read